We know that in breast cancer patients, her2 is mutated in 2 to 3% of primary tumors, the most common mutations occurring in the HER2-negative breast cancer subtype, which has a reported rate of incidence of 70% in the cat [10,47]. This evidence concerns the gene ERBB2 and breast cancer.